Cubist Pushes Trius Drug Forward As Cubicin Comes Up Short
This article was originally published in The Pink Sheet Daily
The antibiotic drug maker is already making advantageous moves after closing one of its two most recent acquisitions, even as its highest-revenue product sees stalled growth.
You may also be interested in...
Cubist will rely on its experience in infectious disease to drive growth of Dificid for Clostridium difficile infection and to launch tedizolid for skin infections, but the commercial market for new antibiotics is daunting and re-creating the success of Cubicin won’t be easy.
The Boston-area company will no longer rely as heavily on the antibiotic Cubicin, once it takes out its partner on a second marketed drug and, separately, a clinical-stage antibiotics company. The deals give Cubist territorial rights to Optimer’s Dificid for C. diff and Trius’s tedizolid for Gram-positive infections for $535 million and $707 million, respectively, plus CVRs.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.